Pulmonary Arterial Hypertension Market worth $9 billion by 2027
The report "Pulmonary Arterial Hypertension Market by Drug Class (SGC Stimulators, Endothelin Receptor Antagonists, Type (Innovative, Generics) – Global Forecast to 2027", is projected to reach USD 9 billion by 2027 from USD 7 billion in 2022, at a CAGR of 5% during the forecast period
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/pulmonary-arterial-hypertension-market-30552023.html
Factors such investment by key market players in launching of novel therapies for pulmonary arterial hypertension is driving the market growth. Furthermore, rising prevalence of PAH is further anticipate to increase the demand for treatment options hence projecting the market growth in coming years. According to the American Lung Association, about 500 to 1000 new PAH patients are being diagnosed every year in the U.S.
Prostacyclin and Prostacyclin Analogs segment likely grow at faster pace during the forecast period of 2022-2027.
Based on the drug class the market is segmented into endothelin receptor antagonists, SGC Stimulators, PDE-5 Inhibitors, prostacyclin and prostacyclin analogs and others. In 2021, the prostacyclin and prostacyclin analogs segment accounted for the largest share of the pulmonary arterial hypertension market. Increasing FDA approvals is rising the demand for the drugs hence projecting the market growth. For instance, in June 2022, United Therapeutic Corporation received FDA approval for Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to enhance exercise ability.
North America to command the largest share of the pulmonary arterial hypertension market in 2021
Based on region, the pulmonary arterial hypertension market is segmented into North America, Europe, the Asia Pacific and ROW. North America accounted for the largest share of the pulmonary arterial hypertension market in 2021. The growth of the North American market is primarily driven by presence of strong healthcare sector, coupled with rising prevalence PAH and chronic diseases in the region. Furthermore, awareness among the patient population and encouraging government initiatives is further anticipated spur the growth of the pulmonary arterial hypertension market in North America.
The major players operating in the pulmonary arterial hypertension market are United Therapeutics Corporation (US), BAYER (Germany), Gilead Sciences, Inc. (US), Johnson & Johnson (US), Viatris Inc. (US), Teva Pharmaceutical Industries Ltd. (Israel) and among others.
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Pulmonary Arterial Hypertension Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
